Interventional Cardiology Perspective

 
 
  • Dropping Aspirin Post PCI: Are We There Yet?   Is P2Y12 inhibitor monotherapy post PCI ready to go mainstream? Michelle O'Donoghue considers the question of when to drop aspirin in the context of recent trials on antiplatelet therapy.
  • Could Colchicine Be the New Aspirin? Michel Zeitouni talks to Jean-Claude Tardif about the COLCOT series of clinical trials testing colchicine, an anti-inflammatory gout drug, for the prevention and treatment of cardiovascular disease.
  • Entering the TWILIGHT Zone of DAPT Duration   Experts from the Mayo Clinic discuss the impact of TWILIGHT, a comparison of ticagrelor monotherapy vs dual-antiplatelet therapy in post-PCI patients.
  • The War on Shock: Is Industry Leading the Charge? Protocols for patients in cardiogenic shock encourage use of mechanical circulatory support and play down palliative care, despite limited supporting data, writes interventional cardiologist Jaya Mallidi.
  • 'Frustration and Disbelief' Over Drug Shortages   Drs Robert Glatter and Paul Biddinger discuss drug shortages, including potential causes and solutions.
  • 15 Studies That Challenged Medical Dogma in 2019 Dr Eric J. Topol's favorite scientific papers challenge medicine's prevailing wisdom. These 15 papers from 2019 did just that.
  • Mandrola's Top 10 Cardiology Stories of 2019 It's probably no surprise that ISCHEMIA and the EXCEL controversy make John Mandrola's annual list for 2019. He also found good news in heart failure and has words of caution for TAVR expansion.
  • Cardiology 2019: Top Trials in Review   'It's like we're in the '90s again.' Drs Gibson and Harrington review top cardiology trials on revascularization, lipid management, and antithrombotics in part 1 of their annual wrap-up.
  • Top News From AHA 2019: Slideshow Results of the highly anticipated ISCHEMIA trial testing the true value of an early invasive strategy in stable ischemic heart disease was the breakout star of this year's scientific sessions.
  • Superiority of Surgery vs Stents in Left Main 'Unarguable'   Prof. John McMurray reviews the EXCEL 5-year data with John Mandrola. The primary composite outcome was similar for the two strategies but 'that's maybe not the most important part of the story'.
  • ISCHEMIA-CKD PI Hopes Study Doesn't Fuel the Flames of Renalism   Principal investigator Sripal Bangalore discusses ISCHEMIA-CKD and its implications for the management of patients with chronic kidney disease and stable CAD.
  • Managing the SIHD Patient in a Post-ISCHEMIA World   Dr O'Donoghue and interventional cardiologists Drs Al-Lamee and Tamis-Holland discuss how the trial results will affect the workup and treatment of patients with stable ischemic heart disease.
  • John Spertus, MD, on the Practice-Changing ISCHEMIA Trial   The ISCHEMIA investigator discusses the implications of the gasp-inducing trial comparing an invasive vs conservative medical therapy strategy in patents with stable ischemic heart disease.
  • AHA 2019Signal of Harm From Impella Has an Easy Answer Two independent observational studies find worse outcomes with the Impella device compared with intra-aortic balloon pump. The time for a randomized controlled trial is now, says John Mandrola, MD.
  • AHA 2019The ISCHEMIA Trial -- Cardiology Changes Today The AHA late-breaking trial comparing an invasive vs medical strategy for patients with stable ischemic disease validates Nobel prize-winning medical conservative Bernard Lown, writes John Mandrola, MD.
  • The Role of Non-statin Therapy for Secondary Prevention of ASCVD A 64-year-old woman with a significant medical history sees her cardiologist for a routine follow-up after a second MI. How do you minimize her risk for future ASCVD events?
  • Mandrola Previews 2019 AHA and the ISCHEMIA Trial All eyes will be on ISCHEMIA in Philadelphia, but a study on asymptomatic aortic stenosis as well as trials in heart failure and cardiogenic shock also piqued Dr John Mandrola's interest.
  • PCI vs CABG in Left Main Disease -- The Surgeons Are Right A claim of equivalence for stents vs surgery in patients with left main coronary artery disease was called into question at EACTS. John Mandrola, MD, takes a closer look at the EXCEL trial controversy.
  • Top News From TCT 2019: Slideshow Research predicted to alter the landscape of aspirin therapy after PCI, plus support for pacemaker-based therapy for hypertension featured prominently at TCT 2019.
  • Not so Fast: How to Avoid Bias Toward Stents in Managing SIHD Channeling Daniel Kahneman's 'Thinking, Fast and Slow,' Dr Jaya Mallidi warns that inherent biases and system 1 thinking, may exaggerate the benefit of stents in SIHD and corrupt shared decision-making.